Dosage Forms of Drugs Used in Psychiatry
https://doi.org/10.30629/2618-6667-2024-22-5-117-124
Abstract
Background: despite the wealth of dosage forms in modern pharmaceuticals, patients with mental pathology mainly use oral forms of drugs. The aim of article is to present the state of the art on practical administration of different drug forms in clinical psychiatry. Method: assessment and discussion of registered drug forms of original substances significance capable to increase the treatment effectiveness. Results: tablet forms are the most relevant in psychiatry, but they are also very diverse: from oral dispersible tablets to film-coated tablets with modified release of the active substance. However, manufacturers do not specifically emphasize the specifics of using a particular dosage form in psychiatry. For patients with chronic disorders, when carrying out long-term basic therapy, long-acting parenteral drugs are used, manufactured using modern technologies that make it possible to control the release of the substance in the current daily dose for weeks and a month after a single consuming. Conclusion: the use of oral forms of drugs may be important for monitoring compliance in patients in hospital settings, and long-acting forms are relevant for treating patients in outpatient practice.
About the Authors
M. V. Anokhina
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
Maria V. Anokhina, Junior Researcher, Scientific and Organizational Department
St. Petersburg
A. Yu. Goncharenko
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
Andrey Yu. Goncharenko, Dr. Sci. (Med.), Leading Researcher, Scientific and Organizational Department,
St. Petersburg
V. L. Kozlovskii
V.M. Bekhterev National Medical Research Center for Psychiatry and Neurology
Russian Federation
Russian Federation
Vladimir L. Kozlovsky, Dr. Sci. (Med.), Leading Researcher, Scientific and Organizational Department
St. Petersburg
References
1. Andrew J Cutler 1, Gregory W. Mattingly Beyond the pill: new medication delivery options for ADHD. CNS Spectr. 2017; Dec;22(6):463-474. doi: 10.1017/S1092852916000936. Epub 2017 Jul 7.
2. Krogmann A, Peters L, von Hardenberg L, Bödeker K, Nöhles VB, Correll CU. Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. CNS Spectr. 2019; Aug;24(S1):38-69. doi: 10.1017/S109285291900124X. PMID: 31482779
3. Oleneva E.V., Ryvkin P.V., Ladyzhenskij M.Ya., Mosolov S.N. Orally Disintegrating Tablets: Potentials in Psychiatry Sovrem. ter. psih. rasstrojstv [Current Therapy of Mental Disorders]. 2018;4:31-39. doi: 10.21265/PSYPH.2018.47.21792
4. Bredberi M. Koncepciya gematoencefalicheskogo bar’era / M. Bredberi; per. s angl. V.I. Kandrora. M.: Medicina, 1983. 480 s.
5. Miroshnichenko II. Rol’ i mesto farmakokinetiki pri razrabotke novykh lekarstvennykh sredstv. Razrabotka i registratsiia lekarstvennykh sredstv. 2014;2(7):152-156.
6. Kozlovskii VL. Crisis in psychopharmacology, or where does the neurochemical paradigm of the XX century lead to? Bekhterev Review of Psychiatry and Medical Psychology. 2011;3:4-7.
7. Brissos S, Veguilla MR, Taylor D, Balanzá-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014 Oct;4(5):198-219. doi: 10.1177/2045125314540297. PMID: 25360245; PMCID: PMC4212490.
8. Leonova MV. Novye lekarstvennye formy i sistemy dostavki lekarstvennykh sredstv: osobennosti peroral’nykh lekarstvennykh form. Ch. 2. Lechebnoe delo. 2009;3:18-26.
9. Sysuev BB, Pletneva IV. Sovremennoe sostoianie issledovanii razrabotok v oblasti innovatsionnykh lekarstvennykh form i ikh modifikatsii. Vestnik VolgGMU. 2014;4(52):7-12.
10. Mebert AM, Aimé C, Alvarez GS, Shi Y, Flor SA, Lucangioli SE, Desimone MF, Coradin T . Silica coreshell particles for the dual delivery of gentamicin and rifamycin antibiotics. J Mater Chem B. 2016 May 14;4(18):3135-3144. doi: 10.1039/c6tb00281a. Epub 2016 Apr 18. PMID: 32263051.
11. Kovaleva EL. Standartizatsiia farmatsevticheskikh substantsii i preparatov v lekarstvennoi forme “tabletki”. Moskva: FGU “NTsESMP”. 2012;287 s. ISBN 978-5-8125-1812-7
12. Shikh EV. Biodostupnost’ peroral’nykh preparatov. RMJ. 2007;2:95-99.
13. Kinon B, Hill A, Liu H, Kollack M, Walker S. Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia (extended referat). P.B. Gannushkin Psychiatry and Psychopharmacotherapy Journal. 2006;4:83-84.
14. Lutova NB. Komplaens i psikhopatologicheskaya simptomatika. Bekhterev Review of Psychiatry and Medical Psychology. 2012;3:59-65.
15. Lutova NB, Petrovskaia IN, Vid VD. Soznanie bolezni i komplaiens bol’nykh psikhozami. Bekhterev Review of Psychiatry and Medical Psychology. 2014.1:10-15.
16. Kozlovskii VL, Lepik OV, Popov MIu, Kosterin DN. Rol’ farmakogennogo faktora v moduliatsii terapevticheskoi komplaentnosti. Bekhterev Review of Psychiatry and Medical Psychology. 2022;56(3):8-12.
17. Klinicheskaya farmakologiya: uchebnik / pod red. V.G. Kukesa. 2-е izd., pererab. M., 2004; 528 s.
18. De Risio A, Lang AP. History and therapeutic rationale of long acting antipsychotics. Curr Clin Pharmacol. 2014 Feb;9(1):39-52. doi: 10.2174/15748847113089990057.
Review
For citations:
Anokhina M.V., Goncharenko A.Yu., Kozlovskii V.L. Dosage Forms of Drugs Used in Psychiatry. Psychiatry (Moscow) (Psikhiatriya). 2024;22(5):117-124. (In Russ.) https://doi.org/10.30629/2618-6667-2024-22-5-117-124
Views:
230
Email this article 
